85P Efficacy and safety of dostarlimab plus carboplatin–paclitaxel in first-line patients with mismatch repair-deficient or microsatellite instability-high recurrent or primary advanced endometrial cancer: An italian real life experience

Key Points

• To evaluate the efficacy and safety of dostarlimab combined with carboplatin and paclitaxel in treating advanced endometrial cancer patients with dMMR or MSI-H.
• Included patients with mismatch repair deficiency or microsatellite instability-high endometrial cancer.
• Utilized dostarlimab alongside carboplatin and paclitaxel as first-line treatment.
• Evaluated clinical outcomes based on RUBY phase III clinical trial data.
• Dostarlimab plus carboplatin–paclitaxel significantly increased progression-free survival compared to controls (exact metrics not provided).
• Substantial benefits were observed particularly in the dMMR/MSI-H subgroup.
• The treatment was well-tolerated with manageable safety profiles.